US Hemp Roundtable Responds to Cannabis Administration and Opportunity Act
“We were very pleased that the draft contained a section that would ensure a regulatory pathway for the sale of hemp-derived CBD as a dietary supplement,” an online update from the U.S. Hemp Roundtable read. “We were concerned, however, that in the draft, hemp-derived ingredients would be subjected to a uniquely onerous regulatory regime, or in some cases, still treated as illegal substances. We strongly believe that non-intoxicating hemp ingredients should be regulated like any other botanical ingredient.”
The U.S. Hemp Roundtable reported it had met with the staffs of all of the sponsors and its input was welcomed. Accordingly, on Friday, the hemp group sent Senators Schumer, Wyden and Booker a comprehensive letter outlining its concerns and offering improvements.
The letter offers five key recommendations:
- Open an additional pathway for the sale of hemp extracts like CBD as food and beverage additives.
- Expand protections from just CBD to all non-intoxicating hemp derivatives and cannabinoids.
- Allow all forms of safety evaluations permitted by law to be used, not just limit manufacturers to new dietary ingredient notifications (NDINs). (This issue is particularly timely given FDA’s rejection last week of two comprehensive and compelling NDIN submissions.)
- Provide a more comprehensive process of determining potential daily serving limits.
- Ensure separate regulatory pathways for non-intoxicating hemp and intoxicating cannabis products